Grant number: 108514 | Funding period: 2023 - 2027
Active
I Fadilah, JA Watson, AP Pasaribu, I Sutanto, EJ Nelwan, K Lidia, M Rajasekhar, IR Elyazar, WR Taylor, K Thriemer, NP Day, JR Poespoprodjo, JA Simpson, RN Price, JK Baird, RJ Commons
2026-07-01
Background: Plasmodium vivax malaria has diverse transmission and relapse patterns in Indonesia. The optimal dose of primaquine to..
Tamiru Shibiru Degaga, Kamala Thriemer, Megha Rajasekhar, Tesfay Abreha, Ashenafi Assefa, Nicholas M Douglas, Endalamaw Gadisa, Asrat Hailu, Jimee Hwang, Gavin CKW Koh, Marcus VG Lacerda, Alejandro Llanos-Cuentas, Daniel Abebe Mekonnen, Julie A Simpson, Fitsum G Tadesse, Walter RJ Taylor, Lorenz von Seidlein, Adugna Woyessa, Asnakew K Yeshiwondim, Daniel Yilma
2026-06-06
BACKGROUND: The 8-aminoquinoline antimalarials are used to prevent P. vivax relapses. Recent evidence suggests high total dose pri..
APN Bareng, KW Wu, E Takashima, DC Argyropoulos, L Smith, MT Naung, R Mazhari, K Schoffer, N Kiernan-Walker, A Abraham, M Lamont, S Mehra, PS Lim, J Sattabongkot, W Monteiro, M Lacerda, J Healer, CE Chitnis, WH Tham, T Tsuboi
2026-06-01
Background Plasmodium vivax poses a major obstacle to malaria elimination because this parasite can lie dormant in the liver for w..
TS Degaga, AP Pasaribu, R Tripura, N Ghanchi, M Rajasekhar, B Adhikari, B Ley, SA Bamboro, FA Jabbar, N Hasibuan, TT Tego, S Zehra, B Qurashi, H Mnjala, G Lee, P Li, AM Kazi, W Safitri, Y Yulita, DSP Siagian
Background: Shorter courses of primaquine and single-dose tafenoquine have potential to improve the prevention of recurrent Plasmo..
A Hysa, DH Opi, J Waterhouse, S Chishimba, JL Horton, N Kingston, HJ Netter, D Wetzel, M Piontek, G Feng, J Sacarlal, C Dobaño, L Kurtovic, JG Beeson
2026-05-01
Background The RTS,S/AS01 malaria vaccine was recently approved for implementation in children, but only provides modest and short..
DH Opi, RJ Longley, E Takashima, T Spelman, Y Tayipto, K Schoffer, J Brewster, L Reiling, BD Wines, B Kiniboro, P Siba, M Harbers, M Hogarth, T Tsuboi, LJ Robinson, I Mueller, JG Beeson
2026-03-10
Understanding immunity against Plasmodium vivax, a leading cause of malaria, will accelerate development of vaccines, which are cu..
R Moss, S Dini, S Kho, BE Barber, PA Buffet, M Rajasekhar, DJ Price, NM Anstey, JA Simpson
2026-01-12
The human spleen significantly influences red blood cell (RBC) dynamics due to its ability to retain and/or remove RBCs from perip..
MK Tully, RJ Commons, JA Simpson, DJ Price
2026-01-01
In silico pharmacokinetic–pharmacodynamic (PK–PD) models are used to inform dose optimisation in antimalarial drug development. He..
P Ghimire, G Dahal, N Adhikari, KR Rijal, S Adhikari, MR Banjara, H Mnjala, G Lee, S Weston, A Rumaseb, A Rai, B Ley, MS Hossain, JA Simpson, M Rajasekhar, B Adhikari, RN Price, BK Lal, K Thriemer
Background: Plasmodium vivax remains a challenge for malaria elimination in Nepal due to its ability to relapse. Radical cure with..
SG Zaloumis, M Rajasekhar, JA Simpson
2025-12-01
Background: Machine learning algorithms have been used to predict malaria risk and severity, identify immunity biomarkers for mala..
Paolo Bareng, Kenneth W Wu, Eizo Takashima, Dionne Argyropoulos, Lauren Smith, Myo Naung, Ramin Mazhari, Kael Schoffer, Nicholas Kiernan-Walker, Anju Abraham, Macie Lamont, Somya Mehra, Pailene Lim, Jetsumon Sattabongkot, Wuelton Monteiro, Marcus Lacerda, Julie Healer, Chetan E Chitnis, Wai-Hong Tham, Takafumi Tsuboi
2025-07-08
BACKGROUND: Plasmodium vivax poses a major obstacle to malaria elimination because it can lie dormant in the liver for weeks or mo..
EA Kearney, AS Heng-Chin, K O'Flaherty, FJI Fowkes
2025-05-01
Antibodies developed against Anopheles mosquito salivary proteins injected during biting may serve as proxy biomarkers of Anophele..
JA Watson, P Mehdipour, R Moss, P Jittamala, S Zaloumis, DJ Price, S Dini, B Hanboonkunupakarn, P Leungsinsiri, K Poovorawan, K Chotivanich, G Bancone, RJ Commons, NPJ Day, S Pukrittayakamee, WRJ Taylor, NJ White, JA Simpson
2025-04-01
Primaquine is the only widely available drug to prevent relapses of Plasmodium vivax malaria. Primaquine is underused because of c..
B Ley, LR Vasquez, A Sitsabasan, B Adhikari, N Adhikari, MS Alam, S Das, P Ghimire, MVG Lacerda, RN Price, KR Rijal, L von Seidlein, A Talukdar, K Thriemer, AW Satyagraha, A Sadhewa, M Rajasekhar, RJ Commons
2025-01-01
Background: Measurement of glucose-6-phosphate dehydrogenase (G6PD) activity guides hypnozoitocidal treatment of P vivax malaria. ..
MK Tully, S Dini, JA Flegg, JS McCarthy, DJ Price, JA Simpson
2024-09-01
The rise of multidrug-resistant malaria requires accelerated development of novel antimalarial drugs. Pharmacokinetic–pharmacodyna..
EA Kearney, P Amratia, SY Kang, PA Agius, KA Alene, K O’Flaherty, WH Oo, JC Cutts, W Htike, D Da Silva Goncalves, Z Razook, AE Barry, D Drew, A Thi, KZ Aung, HK Thu, MM Thein, NN Zaw, WYM Htay, AP Soe
2024-06-11
The World Health Organization identifies a strong surveillance system for malaria and its mosquito vector as an essential pillar o..